Perosphere Technologies Welcomes Michael Grosso to its Advisory Board

Perosphere Technologies Inc. has named Michael A. Grosso, M.D., to its Advisory Board. As a seasoned pharmaceutical industry executive and former academic cardiothoracic surgeon, Grosso will help the company develop and commercialize diagnostic tools.
 
“We are thrilled to welcome Dr. Michael Grosso to Perosphere’s Advisory Board,” Perosphere Technologies CEO Dr. Sasha Bakhru said. “His knowledge of DOACs and experience in developing therapeutic solutions for patients fully aligns with Perosphere’s mission to offer a complete diagnostic picture of a patient’s coagulation status. His extensive expertise, both in and out of the operating room, and his commitment to cross-functional and cross-cultural collaboration, will ensure that the needs of physicians and patients are fully considered and incorporated into product features and capabilities as we develop and promote the use of Perosphere’s technology.”
 
Grosso brings to his new role more than four decades of healthcare knowledge, including expertise in cardiovascular, hematology, and thrombosis therapeutic areas and drug development. After graduating from The Perelman School of Medicine at the University of Pennsylvania, Grosso spent 11 years as a cardiothoracic surgeon. He later joined Sanofi as a Cardio/Thrombosis medical advisor before joining Daiichi Sankyo in 2010, where he took on a variety of medical leadership roles. Grosso is responsible for the pre-clinical, clinical (Phase 1-4), and lifecycle management of the specialty medicine portfolio globally for the orphan/rare genetic disease, neurology, inflammation, ophthalmology, cardiovascular/metabolic, and thrombosis/thrombolysis/hemostasis therapeutic areas.

“The technology Perosphere is developing excites me both as a physician and as a leader in clinical development. There is a clear need for more and better point-of-care diagnostics in the coagulation arena, both from a patient care perspective and for use in clinical trials for more timely results,” Grosso stated. “I am honored to have been asked to join the Advisory Board in order to support Perosphere’s great work. Finding ways for physicians to diagnose more accurately and treat patients more confidently have been key goals in my career that dovetail perfectly with Perosphere’s important mission.”
 
A private medical technologies company, Perosphere developed and is commercializing its PoC (point-of-care) Coagulometer, which informs diagnosis, treatment, and prevention through precision data, made immediately accessible to all. It reportedly is the only point-of-care diagnostic tool that effectively and swiftly tests clotting times across drug classes, including DOACs. The fast diagnosis and related appropriate treatment decisions the PoC Coagulometer enables will help establish a new standard of care in hospitals, at the point-of-care, for patients at risk for bleeding and has the potential to improve efficiency, provide significant cost savings, and better patient outcomes, according to the company. The PoC Coagulometer has received CE Mark approval in the European Union but is not yet cleared for use in the United States.